Genmab A/S (GNMSF) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$284.55

-5.83 (-2.01%)

(As of 04/19/2024 ET)

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Source

Source	Headline
	Genmab Acquires A Missing Piece For Its Pipeline seekingalpha.com - April 16 at 5:33 PM
	Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln markets.businessinsider.com - April 16 at 7:32 AM
	Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $304.41 americanbankingnews.com - April 12 at 3:08 AM
	Truist Financial Keeps Their Buy Rating on Genmab (GMAB) markets.businessinsider.com - April 9 at 5:33 PM
	ProfoundBio discovers the joys of having a wealthy owner benzinga.com - April 8 at 1:36 PM
	30 Biggest Biotechnology Companies in the World finance.yahoo.com - March 17 at 8:59 AM
	Passing of Genmab A/S’ Annual General Meeting finance.yahoo.com - March 13 at 12:58 PM
	Genmab: Recent Updates Support The Growth Narrative seekingalpha.com - February 21 at 5:40 AM
	4 Analysts Assess Genmab: What You Need To Know markets.businessinsider.com - February 20 at 1:00 PM
	Genmab A/S’ New Regulation Risk – A Cause for Worry? msn.com - February 15 at 12:38 PM
	Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript finance.yahoo.com - February 15 at 12:38 PM
	Notice to Convene the Annual General Meeting of Genmab A/S finance.yahoo.com - February 15 at 7:38 AM
	Genmab Files Annual Report with the U.S. Securities and Exchange Commission finance.yahoo.com - February 14 at 4:15 PM
	Genmab: Growth Is Still a Better Choice finance.yahoo.com - February 14 at 4:15 PM
	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer finance.yahoo.com - February 2 at 7:26 AM
	Cracking The Code: Understanding Analyst Reviews For Genmab markets.businessinsider.com - January 29 at 8:44 AM
	Grant of Restricted Stock Units and Warrants to Employees in Genmab finance.yahoo.com - January 25 at 5:23 PM
	Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen finance.yahoo.com - January 22 at 7:38 PM
	HRMY or GMAB: Which Is the Better Value Stock Right Now? finance.yahoo.com - December 7 at 2:14 PM
	Genmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 8 at 7:38 PM
	Genmab reports 9M results msn.com - November 7 at 6:13 PM
	Genmab Announces Financial Results for the First Nine Months of 2023 finance.yahoo.com - November 7 at 1:13 PM
	Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) finance.yahoo.com - November 2 at 10:08 AM
	Genmab and Seagen report positive data from Phase III TIVDAK trial msn.com - October 23 at 11:23 PM
	Seagen, Genmab update Phase 3 data for uterine cancer therapy msn.com - October 23 at 6:22 PM
	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023 finance.yahoo.com - October 17 at 6:28 AM
	What 13 Analyst Ratings Have To Say About Genmab benzinga.com - October 13 at 1:47 PM
	Diversified Stock Portfolio: 10 Sector ETFs and International ETFs to Buy finance.yahoo.com - September 28 at 1:23 PM
	EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) finance.yahoo.com - September 25 at 9:13 AM
	EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) finance.yahoo.com - September 25 at 9:13 AM
	Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) finance.yahoo.com - September 25 at 9:13 AM
	Genmab : Phase 3 Trial Of TIVDAK In Recurrent Or Metastatic Cervical Cancer Meets Primary Endpoint markets.businessinsider.com - September 4 at 9:52 PM
	Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone finance.yahoo.com - September 4 at 4:52 PM
	Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy finance.yahoo.com - September 4 at 4:52 PM
	UPDATE 1-Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint finance.yahoo.com - September 4 at 4:52 PM
	Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference finance.yahoo.com - August 28 at 2:26 PM
	Genmab Announces Financial Results for the First Half of 2023 finance.yahoo.com - August 3 at 3:39 PM
	Genmab Updates 2023 Financial Guidance finance.yahoo.com - July 28 at 1:14 AM
	Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators? finance.yahoo.com - July 2 at 9:55 AM
	Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) finance.yahoo.com - June 27 at 7:35 PM
	Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’ finance.yahoo.com - June 22 at 7:28 AM
	Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 finance.yahoo.com - June 9 at 4:17 AM
	Expert Ratings for Genmab benzinga.com - June 6 at 2:30 PM
	Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference finance.yahoo.com - June 6 at 4:28 AM
	EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) finance.yahoo.com - May 19 at 2:46 PM
	UPDATE 2-US FDA approves Genmab-AbbVie's blood cancer therapy finance.yahoo.com - May 19 at 2:46 PM
	Genmab Announces Financial Results for the First Quarter of 2023 finance.yahoo.com - May 10 at 11:04 AM
	Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen finance.yahoo.com - April 20 at 11:27 PM
	Analyst Ratings for Genmab msn.com - April 20 at 6:26 PM
	Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength? finance.yahoo.com - April 18 at 8:58 AM

Get Genmab A/S News Delivered to You Automatically

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

GNMSF Media Mentions By Week

GNMSF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GNMSF
News Sentiment
▼
-0.18

0.52
▲
Average
Medical
News Sentiment

GNMSF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GNMSF Articles
This Week
▼
2

0
▲
GNMSF Articles
Average Week

Get Genmab A/S News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (OTCMKTS:GNMSF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genmab A/S (GNMSF) News Today

GNMSF Media Mentions By Week

GNMSF Media Sentiment

GNMSF News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info